Abstract The aberrant DNA methylation of the tumor suppressor genes involved in DNA Damage Response (DDR) signaling and cell cycle regulation may lead to the tumorigenesis.
Introduction
In developing countries, Oral Squamous Cell Carcinoma (OSCC) is the most prevalent epithelial malignancy influencing the oral cavity (Parkin et al. 2001) . OSCC accounts for more than 90 % of all oral neoplasms, therefore it is often used interchangeably with oral cancer (Choi and Myers 2008) . The incidence rate of oral cancer is 1.08 and 1.25 per 100,000 in men and women, respectively (Kordi-Tamandani et al. 2010a) . Growth of OSCC is a multistep process, resulting from a combination of genetic susceptibility and environmental risk factors including tobacco and alcohol consumption, chronic inflammation and viral infection (Chien et al. 2013 ). Oncogenes and tumor suppressor genes are the two major groups of pro-tumorigenic genes which promote tumorigenesis whenever up-regulated or down-regulated, respectively (Hanahan and Weinberg 2000) . The down-regulation of tumor suppressor genes is preceded through various epigenetic modifications, mutations, loss of heterozygosities and deletions (Perez-Sayans et al. 2009 ). The epigenetic suppression of genes take place through methylation of CpG islands or histone modifications such as methylation of histone 3, lysine 27 (H3K27) (Rad et al. 2016) .
Large Tumor Suppressor gene 1 (LATS1) and Large Tumor Suppressor gene 2 (LATS2), which located on the 6q25.1 and 13q12.11 chromosomes, respectively; are key tumor suppressor genes in the cell cycle regulation and DDR signaling (Najafi et al. 2016) . LATS1/2 localize to the mitotic apparatus and regulate cell cycle through G2-M arrest and G1-S arrest, respectively (Xia et al. 2002; Li et al. 2003) . Novel Aurora ALats1/2-Aurora B axis directs proper chromosome segregation and cytokinesis during mitosis (Yabuta et al. 2016; . Also, these genes are main tumor suppressors of hippo signaling pathway which has profound effects on normal cell fate and tumorigenesis (Aqeilan 2013) . Furthermore, in response to DNA damage, LATS1/2 serve as tumor suppressor in Chk1-Lats2-14-3-3 and Chk1-Lats2-p21 axes. Chk1-Lats2-14-3-3 regulates the P-body formation in response to DNA damage and Chk1-Lats2-p21 axis facilitates apoptosis following high levels of UV radiation, thereby both of the mentioned signals eliminate damaged cells (Scrace and O'Neill 2012; Okada et al. 2011; Suzuki et al. 2013) .
Deregulation of LATS1/2 genes through methylation have been examined in a number of malignancies such as lung cancer, breast cancer, astrocytoma and colorectal cancer (Sasaki et al. 2010; Jiang et al. 2006; Takahashi et al. 2005; Wierzbicki et al. 2013) . Our aim was to extrapolate the status of LATS1/2 promoter methylation and mRNA expression levels in OSCC patients.
Materials and methods
Subject 70 paraffin embedded tissues of OSCC (mean age 54.37 ± 14) and 70 oral mucosa biopsies as controls (mean age 41 ± 14) were obtained from oral and dental disease research center of Zahedan University of Medical Sciences. All clinicopathological information of the patients and the controls filled out by pathologist. The institutional review board approved this study and all participants confirmed the consent form.
DNA extraction and modification
Genomic DNA was isolated from tumor and healthy tissue samples as previously described (Kordi-Tamandani et al. 2010b) . Sodium bisulfite modification was performed on 2 μg of DNA to treat un-methylated cytosine to uracil, while leaving methylated cytosine unaltered according to the Wizard® DNA Clean-Up System (Promega, Madison, WI).
Methylation-specific PCR (MSP)
Gene promoters were recognized through online ensemble database. Then sequences of the considered genes were applied to design methylated and un-methylated primers, using MethPrime online software (http://www.urogene.org/cgibin/methprimer/methprimer.cgi).
1 μl of bisulfite-modified DNA and 0.5 μL of each primer (10 mmol/l) were added to each AccuPower® HotStart PCR PreMix tube (Cat. No. k-5050, Bioneer Company) which contains lyophilized PCR master mix; Taq DNA polymerase, dNTPs, reaction buffer, tracking dye, and patented stabilizer, then the reaction reached to a final volume of 20 μl using nuclease -free double-distilled water. MSP reactions were subjected to an initial incubation 95°C for 5 min, followed by 40 cycles (95°C for 40 s, the annealing temperature for LATS1: M = 53°C, U = 57°C; LATS2: M = 55.5°C, U = 55°C for 40 s and extension at 72°C for 40 s). Final incubation was completed at 72°C for 10 min. It should be pointed out that a positive control (in vitro methylated and bisulfite-treated human placenta DNA) and a negative control (no sample) were incorporated in all reactions. The designed primers were shown in Table 1 .
Analysis of mRNA expression
Total RNA was extracted from fixed paraffin embedded tissues, using the High Pure FFPE RNA Micro Kit) Cat No: 04,823,125,001. As well as, isolation of total RNA from fresh normal samples was performed, using Cinna Pure RNA Purification Kit (Cat No: PR891620). cDNA Synthesis Kit (Fermentas, Cat No: K1621) was utilized to reverse-transcribe 1 μg of RNA to the cDNA in a final volume of 20 μl. To evaluate the gene expression, the M methyl, U unmethyl cDNA was amplified using specific primer (Table 2) and SYBR green method in Applied Biosystems® 7500 machine (USA). The following optimal thermal condition was applied: 10 min at 95°C, 35 cycles of 15 s at 95°C, 30 s at 57°C, and 45 s at 72°C. The real-time PCR data was normalized by 18sRNA.
Statistical analysis
Statistical analyses were performed using SPSS version 23.0 (SPSS, IBM). Chi-square test was applied to analyze the correlation between clinicopathological parameters and promoter methylation status. Methylation status of LATS1/2 genes and the risk of OSCC development through promoter methylation were assessed using Logistic Regression. The Mann-Whitney test compared mRNA expression data (CT target/Ct housekeeping) between cases and controls. The p ≤ 0.05 was considered statistically significant.
Results
The promoter of LATS1/2 gene was methylated in OSCC Our data revealed that the promoters of LATS1/2 were methylated in OSCC patients. (Table 3) .
Correlation between methylation statuses of LATS1/2 with clinicopathological data
There was significant correlation between gender and methylation status of LATS1 (p = 0.02). There was no correlation between other clinicopathological data (age, gender and stage) and methylation status of LATS1 and LATS2 (Table 4 and  Table 5 , respectively).
Decreased mRNA expression levels of LATS1/2 in OSCC patients
The mRNA expression Analysis of LATS1/2 genes in OSCC relative to controls revealed the decreased expression of both genes (1.74 ± 0.15 in case vs. 2.10 ± 0.24 in controls in LATS1 (p < 0.001)) and (1.96 ± 0.096 in cases vs. 1.31 ± 0.077 in controls in LATS2 (p < 0.001)) ( Table 6 ).
Discussion
A recent study has found reduced expression of DDR signaling genes such as ATM, Mre 11 and H2AX in OSCC cell lines (Wang et al. 2012 ). However, little is known about the LATS1/2 genes in oral cavity cancers. The data of the current study elucidated that DNA methylation mediates reduction in mRNA expression levels of LATS1/2 in OSCC patients. LATS1/2 protein kinases control cell fate through different signaling pathways . Overexpression of LATS1 results in G (2)/M arrest through inhibiting the CDC2 kinase activity, whereas LATS2 regulates G1/S transition via modulating the kinase activity of Cyclin E/CDK2 (Xia et al. 2002; Li et al. 2003) . Furthermore, at the onset of mitosis, LATS2 influences spindle formation to control precise segregation (Li et al. 2003) . In response to mitotic damage, LATS2 prevents damage through inhibiting Mdm2, which in turn stabilizes p53 protein (Aylon et al. 2006) . Another impressive role of LATS2 in response to damage is apoptosis triggering Chi-square test *M methyl, U unmethyl through phosphorylation of ASPP1 in Lats2-ASPP1-p53 axis which shunts p53 to pro-apoptotic promoters and promotes apoptosis (Aylon et al. 2010) . Unlike LATS2 gene, LATS1 gene achieves mentioned activities through RASSF1A → MST2 → LATS1 pathway, which finally induces apoptosis through blocking Mdm2 and leading to p53 stabilization (Matallanas et al. 2011) . LATS1/2 on the hippo signaling pathway phosphorylate YAP/TAZ dimer which leads to shift the dimer from cytoplasm to nuclear. Eventually, YAP/TAZ stimulate transcription of TEAD factors which affect cell proliferation, metastasis and epithelial-to-mesenchymal transition (EMT) (Piccolo et al. 2014) . Moreover, the phosphorylation of LATS2 on Ser380 by Aurora A and its interaction with Aurora B in ALB pathway (Aurora A-Lats1/2-Aurora B axis) guarantee centrosome separation in response to mitotic signals. On the other hand, LATS2 could be phosphorylated on Ser83 by Aurora A which led to LATS2 centrosomal localization during interphase for centrosome maturation. Intriguingly, after microtubule damage ALB pathway prevents from aneuploidy through phosphorylation of Aurora B by LATS1/2 genes which form a tetraploidy checkpoint together with P53 (Yabuta et al. 2016; Furth and Oren 2011) . Recently, Yabuta et al. (2016) reported LATS1/2 phosphorylate inner centromere protein (INCENP) at S894 which in turn activates Aurora B that this is necessary for proper cytokinesis completion in multipolar division (Yabuta et al. 2016) .
LATS1/2 genes control cell cycle gates through abovementioned pathways; therefore their down-regulation through promoter methylation could give rise to various malignancies. Recently, it was demonstrated that reduced mRNA expression levels of LATS1/2 genes result in decreased entry to the quiescence stage (G0) and increased of cell growth (Sadasivam and DeCaprio 2013) . In line with this study, A number of articles displayed the downregulation of LATS1/2 genes through promoter methylation in different types of malignant and benign tumors including lung cancer, human astrocytoma, breast cancer, colorectal cancer and pterygium (Najafi et al. 2016; Sasaki et al. 2010; Jiang et al. 2006; Takahashi et al. 2005; Wierzbicki et al. 2013) . The status of LATS1/2 promoter methylation and mRNA expression changes between these tumors has been summarized in Table 7 .
Until now, previous studies have indicated the promoter methylation and mRNA expression profiles of P14ARF, MGMT, CDH1, APC, ATM, P15INK4b, P16INK4a, FADD, FAS, ERK and RAF1 in OSCC (Kordi-Tamandani et al. 2010b; Rigi-Ladiz et al. 2011; Kordi-Tamandani et al. 2012; Saberi et al. 2014; Kordi-Tamandani et al. 2014) . Taken together, the outcomes of the current study presented novel methylation markers for designing drugs that modify methylation statuses in OSCC (Mikeska and Craig 2014) .
In conclusion, our results showed the down-regulation of LATS1/2 genes through methylation of their promoters. We propose to use advanced molecular techniques such as RNAseq in various genetic populations to identify the down-stream transcription factors of both genes for exploring the molecular mechanism of these deregulations in OSCC (Zhang et al. 2013; Tuch et al. 2010) . 
